Sexual Health: Herpes (HSV-1 and HSV-2) Management

Introduction

Herpes simplex virus (HSV) comprises two distinct but closely related serotypes: HSV‑1 and HSV‑2. Both viruses are enveloped, double‑stranded DNA viruses belonging to the Herpesviridae family. HSV infections are among the most common sexually transmitted infections (STIs) worldwide, with significant implications for public health, clinical practice, and pharmacologic intervention. The epidemiology of HSV has evolved over the past decades, with a noted increase in HSV‑2 prevalence among certain populations and a shift towards oral HSV‑1 acquisition in sexual contexts. Understanding the virology, clinical manifestations, diagnostic modalities, and pharmacologic management of HSV is essential for clinicians, pharmacists, and researchers engaged in sexual health.

• Learning Objectives:
  1. Describe the virologic characteristics and life cycle of HSV‑1 and HSV‑2.
  2. Identify key clinical presentations and diagnostic criteria for HSV infections.
  3. Explain the pharmacologic principles underlying antiviral therapy for HSV.
  4. Evaluate the evidence for episodic versus suppressive treatment strategies.
  5. Apply patient‑specific considerations, including pregnancy, immunocompromise, and drug interactions, to HSV management.

Fundamental Principles

Virology and Pathogenesis

HSV is characterized by a linear, double‑stranded DNA genome of approximately 152 kilobases, encapsulated within a nucleocapsid, surrounded by a tegument layer and an envelope derived from host cell membranes. The envelope contains glycoproteins gD, gB, gH, and gL, which facilitate attachment and fusion with host cell membranes. Viral entry is mediated primarily through interactions between gD and cellular receptors such as nectin‑1 or heparan sulfate proteoglycans. Once inside, the virus establishes latency within sensory ganglia, with the viral genome maintained as an episome. Periodic reactivation leads to viral shedding and clinical lesions.

Clinical Manifestations

HSV infections are classified into primary and recurrent disease. Primary infection typically presents with prodromal symptoms—burning, tingling, and itching—preceding vesicular eruptions. In HSV‑1, primary lesions often involve the oral mucosa, whereas HSV‑2 primarily targets the anogenital region. Recurrent lesions are usually milder, shorter in duration, and can occur anywhere along the distribution of the involved nerve. Atypical presentations include genital herpes with no visible lesions, atypical mucocutaneous eruptions, or disseminated disease in immunocompromised hosts.

Terminology

• Incidence – The number of new cases per population unit over a specified period.
• Prevalence – The proportion of a population with a disease at a specific time.
• Latency – The dormant phase of HSV within neuronal tissues.
• Reactivation – The return of viral replication from latency, often triggered by stress or immunosuppression.
• Suppressive therapy – Continuous antiviral treatment aimed at reducing recurrence frequency and viral shedding.
• Episodic therapy – Treatment initiated at the onset of an outbreak to shorten duration and severity.

Detailed Explanation

Mechanisms of Antiviral Action

Current antiviral agents target the viral DNA polymerase complex. Two main classes dominate clinical practice: nucleoside analogues and nucleoside monophosphate analogues. The most widely used agents include acyclovir, valacyclovir, famciclovir, and penciclovir. These compounds undergo phosphorylation by viral thymidine kinase (TK) to generate the active triphosphate form. The active triphosphate competes with deoxycytidine triphosphate for incorporation into viral DNA, leading to chain termination and inhibition of viral DNA synthesis. The selectivity for viral TK over host enzymes confers a favorable therapeutic index. However, resistance may arise through mutations in the viral TK gene or DNA polymerase gene, particularly in immunocompromised patients.

Pharmacokinetics

Oral acyclovir is characterized by low oral bioavailability (~20%) and a short elimination half‑life (t_1/2 ≈ 2–3 h). Valacyclovir, a prodrug of acyclovir, achieves higher plasma concentrations due to improved intestinal absorption, with a bioavailability of approximately 55%. Famciclovir is converted to penciclovir, yielding plasma concentrations similar to oral acyclovir. The pharmacokinetic equation for a one‑compartment model with first‑order elimination is: C(t) = C₀ × e⁻ᵏᵗ, where k = ln(2)/t_1/2. The area under the concentration–time curve (AUC) is calculated as AUC = Dose ÷ Clearance. The therapeutic target for suppressive therapy is a trough concentration (C_min) of at least 0.5 µg/mL, though actual therapeutic thresholds remain debated.

Mathematical Modeling of Viral Shedding

Mathematical models have been employed to quantify HSV shedding dynamics. A simple linear regression model relates shedding frequency (Sf) to suppressive drug concentration (C) as: Sf = a × e⁻ᵇC, where a represents baseline shedding without therapy and b denotes the efficacy parameter for drug concentration. Empirical data suggest that increasing C from 0.5 µg/mL to 3 µg/mL can reduce shedding frequency by up to 90 %. These models inform dosing strategies for suppressive regimens.

Factors Influencing Treatment Response

• Immune status – Immunosuppressed individuals exhibit higher shedding rates and may require higher dosing or alternative agents.
• Drug pharmacodynamics – Adequate intracellular activation by viral TK is necessary; TK-deficient strains reduce efficacy.
• Adherence – Poor adherence diminishes drug exposure, increasing recurrence risk.
• Drug interactions – Renal clearance of antivirals may be affected by nephrotoxic agents or medications that compete for tubular secretion.
• Genetic polymorphisms – Variations in hepatic enzymes may alter prodrug conversion rates (e.g., valacyclovir to acyclovir).

Clinical Significance

Relevance to Drug Therapy

Antiviral therapy for HSV serves multiple objectives: reducing lesion severity, shortening outbreak duration, decreasing viral shedding, and lowering transmission risk. Suppressive therapy has been shown to reduce genital lesion recurrence from an average of 3–5 times per year to 0–2 times, and to decrease viral shedding by 60–90 %. Episodic therapy, when initiated within 24 h of prodromal symptoms, can reduce outbreak duration from 7–10 days to 2–4 days.

Practical Applications

In routine practice, clinicians must balance efficacy, safety, patient preference, and cost. Oral acyclovir is effective but requires multiple daily dosing, potentially compromising adherence. Valacyclovir and famciclovir offer once or twice daily dosing, improving adherence. Renal function assessment is mandatory prior to initiation; dose adjustments follow the following guidelines: for acyclovir, reduce dose by 50 % for CrCl 30–50 mL/min and discontinue for CrCl < 20 mL/min. For valacyclovir, reduce by 50 % for CrCl 30–60 mL/min and discontinue for CrCl < 30 mL/min.

Clinical Examples

• Example 1: A 28‑year‑old woman presents with a primary HSV‑2 genital outbreak. She is immunocompetent and has normal renal function. Episodic therapy with valacyclovir 1 g PO bid for 7 days is initiated. She reports rapid symptom resolution within 3 days.
• Example 2: A 45‑year‑old man with HIV (CD4 = 350 cells/µL) experiences frequent recurrences. Suppressive therapy with famciclovir 500 mg PO bid is started. After 3 months, recurrence frequency decreases from 4 per year to 1 per year.
• Example 3: A 32‑year‑old man with chronic kidney disease (CrCl = 25 mL/min) develops HSV‑1 mucocutaneous lesions. Valacyclovir is avoided; instead, oral acyclovir 400 mg PO q12h is prescribed with close monitoring for nephrotoxicity.

Clinical Applications/Examples

Case Scenario 1: Primary HSV‑2 Infection in a Young Adult

A 22‑year‑old male presents with painful genital vesicles and dysuria. Physical examination reveals multiple erythematous vesicles on the penile shaft and scrotum. Rapid antigen testing confirms HSV‑2. The patient is educated about the chronic nature of HSV, the importance of notifying partners, and the use of condoms. Suppressive therapy is not indicated at this stage; episodic valacyclovir 1 g PO bid for 7 days is prescribed to reduce lesion duration. The patient is instructed to resume sexual activity after lesions have completely healed and to use condoms during the entire course of therapy.

Case Scenario 2: Recurrent HSV‑1 Ocular Involvement

A 55‑year‑old woman reports recurrent blisters on the eyelid margins, itching, and photophobia. Examination shows keratoconjunctivitis secondary to HSV‑1. Oral famciclovir 500 mg PO q12h for 7 days is initiated. Adjunctive topical antiviral therapy with trifluridine eye drops is prescribed. The patient is counseled to avoid eye rubbing and to report any worsening symptoms promptly. A suppressive regimen of famciclovir 250 mg PO q12h is considered if recurrences persist.

Case Scenario 3: HSV in Pregnancy

A 30‑year‑old woman at 28 weeks gestation presents with genital lesions. HSV‑2 PCR is positive. She is immunocompetent, with normal renal function. Episodic valacyclovir 1 g PO bid for 7 days is started. She is advised to avoid sexual activity until the lesions resolve. At delivery, a perineal examination is performed; if lesions are present, a cesarean section is considered to reduce neonatal transmission. Postpartum, suppressive therapy is initiated to reduce recurrence risk.

Problem‑Solving Approach for Antiviral Resistance

1. Confirm clinical suspicion of resistance via repeated outbreaks despite adequate therapy.
2. Obtain lesion swab for viral culture and TK mutation analysis.
3. If TK mutations are identified, consider a higher‑dose acyclovir or switch to a drug with a different mechanism, such as foscarnet.
4. In severe cases, intravenous acyclovir 5 mg/kg q8h is administered, monitoring renal function.
5. For patients with renal impairment, alternative agents like famciclovir may be preferred if clearance is adequate.

Summary / Key Points

• HSV‑1 and HSV‑2 share a common life cycle characterized by lytic replication and latency within sensory ganglia.
• Antiviral therapy targets viral DNA polymerase; efficacy depends on viral TK activity and adequate drug concentrations.
• Suppressive therapy reduces recurrence frequency and viral shedding, whereas episodic therapy focuses on shortening individual outbreaks.
• Renal function dictates dosing; patients with CrCl < 30 mL/min require dose adjustments or alternative agents.
• Patient counseling should address transmission prevention, partner notification, adherence strategies, and safe sexual practices.
• Resistance mechanisms involve mutations in TK or DNA polymerase genes; higher‑dose or alternative agents may be necessary.
• Mathematical models of shedding dynamics can guide suppression dosing, highlighting the inverse relationship between drug concentration and shedding frequency.
• Special populations—pregnant women, immunocompromised hosts, and patients with renal disease—require individualized therapeutic regimens.

By integrating virologic principles, pharmacologic mechanisms, and clinical evidence, practitioners can optimize HSV management, reduce disease burden, and improve patient outcomes within sexual health practices.

References

1. Bennett PN, Brown MJ, Sharma P. Clinical Pharmacology. 12th ed. Edinburgh: Elsevier; 2019.
2. Waller DG, Sampson AP. Medical Pharmacology and Therapeutics. 6th ed. Edinburgh: Elsevier; 2022.
3. Feather A, Randall D, Waterhouse M. Kumar and Clark's Clinical Medicine. 10th ed. London: Elsevier; 2020.
4. Ralston SH, Penman ID, Strachan MWJ, Hobson RP. Davidson's Principles and Practice of Medicine. 24th ed. Edinburgh: Elsevier; 2022.
5. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.